A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs CXA 10 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Complexa
- 02 Feb 2018 Status changed from planning to not yet recruiting.
- 26 Jul 2017 According to Complexa media release, this trial will initiate in early 2018.
- 20 Nov 2015 New trial record